Studies how emotions, cold and insulin affect blood flow and sugar use in obesity
Tests how emotions, cold and insulin affect blood flow in adults with obesity.
Plain-language title generated from the registry record
Registry title: Total-body Glucose Utilization in Obesity
Key facts
- Where
- Turku, FinlandSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 60 years old?
Source: NCT06739473, who can take part
Where in Finland
- Turku PET CentreTurku, FinlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Turku University Hospital
- Trial code
- NCT06739473
- Record updated
- 18 December 2024
- Original description
There are three goals for this study. One is to investigate how different emotions and exposure to cold affect blood flow in the body. The second aim is to study how insulin affects blood flow and tissue glucose uptake, and to study whether this effect is altered in obesity. Last, the study focuses on establishing the lowest dose of a PET radiotracer, oxygen-15 labelled water, that can be used in clinical studies with a new whole-body PET scanner.Read full original descriptionShow less
Total-body Glucose Utilization in Obesity
There are three goals for this study. One is to investigate how different emotions and exposure to cold affect blood flow in the body. The second aim is to study how insulin affects blood flow and tissue glucose uptake, and to study whether this effect is altered in obesity. Last, the study focuses on establishing the lowest dose of a PET radiotracer, oxygen-15 labelled water, that can be used in clinical studies with a new whole-body PET scanner.
Inclusion: Age 20-60 years; BMI either 18.5-25 kg/m2 or above 30 kg/m2; Use of hormonal contraception for women in child bearing age.
Exclusion: In the group with obesity: current or previous use of GLP-1-agonists or insulin; Previous participation in PET studies; Previous significant exposure to radiation; In the lean group history of obesity or type 2 diabetes; History of eating disorders; Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results; Smoking, use of narcotics, excessive use of alcohol; Claustrophobia; Active plans for concieving (both sexes).